Finding cultivars suited to local conditions is a key to success. Hemp prefers warm growing conditions, and the best European fiber strains are photoperiodically adapted to flowering in southern Europe, which provides seasons of at least 4 months for fiber, and 5.5 months for seed production. Asian land races are similarly adapted to long seasons. In Canada, many of the available cultivars flower too late in the season for fiber production, and the same may be predicted for the northern US. Fiber production should also be governed by availability of moisture throughout the season, and the need for high humidity in the late summer and fall for retting, so that large areas of the interior and west of North America are not adapted to growing fiber hemp. The US Corn Belt has traditionally been considered to be best for fiber hemp. There are very few cultivars dedicated to oilseed production (such as ‘Finola’ and ‘Anka’) or that at least are known to produce good oilseed crops (such as ‘Fasamo’ and ‘Uniko-B’). Oilseed production was a specialty of the USSR, and there is some likelihood that northern regions of North America may find short-season, short-stature oilseed cultivars ideal.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Industrial hemp is a versatile agricultural plant which could one day be a valuable crop option for Pennsylvania farmers. The Commonwealth of Pennsylvania has taken some important steps toward making that a reality. Following Governor Wolf’s signing of the Industrial Hemp Research Act, Number 92 in 2016, the Pennsylvania Department of Agriculture’s Industrial Hemp Research Pilot Program started issuing permits for research & growth of industrial hemp in 2017. Pennsylvania’s industrial hemp legislation was sparked by the passage of the 2014 Farm Bill, which gave federal permission for institutions of higher education or state Departments of Agriculture to research the cultivation and marketing of industrial hemp. As part of Pennsylvania’s Research Pilot Program, industrial hemp was legally grown in the Commonwealth after an 80 years hiatus. The Department of Agriculture has issued 35 research permits in the last two years to institutions of higher education and to farmers, business or individuals in contract with the Department to participate in the research of industrial hemp cultivation and marketing in Pennsylvania. In 2018, 35 research permits were issued to researchers, who cultivated industrial hemp in 25 Pennsylvania counties.
Hemp plants can be vulnerable to various pathogens, including bacteria, fungi, nematodes, viruses and other miscellaneous pathogens. Such diseases often lead to reduced fiber quality, stunted growth, and death of the plant. These diseases rarely affect the yield of a hemp field, so hemp production is not traditionally dependent on the use of pesticides.
Canabidol™ CBD cannabis oil (CBD Oli) is derived from EU approved, UK & US legal, industrial hemp (Cannabis Sativa L.) The active ingredient is Cannabidiol as our products are THC free, meaning that they are non psychoactive so will not get you high. CBD Oil (Cannabidiol) is not scheduled and is found in all hemp products which makes it legal in both the UK and US. Manufactured in England to the highest standards Canabidol™ is now sent out from our United Kingdom distribution centre. You can also purchase our range of CBD oil products direct from one of our many stores across the UK.
“The plan? Whip the public into a frenzy over ill effects of marijuana, the psychoactive leaves and flowers of the hemp plant; the reputation of the fibers and seeds used by industry would be posing little threat to society emerged as the ‘assassin of youth.’ The strategy worked. In 1937, with virtually no warning, Congress announced a prohibitive tax on hemp, effectively ending the production and sale of the plant in the United States.
In 1951, Congress passed the Boggs Act, which for the first time included Cannabis with narcotic drugs. In 1970, with the passage of the Controlled Substances Act, marijuana was classified by Congress as a Schedule I drug. Drugs in Schedule I are distinguished as having no currently accepted medicinal use in the United States. Other Schedule I substances include heroin, LSD, mescaline, and methaqualone.
Canabidol™ CBD Cannabis Oil (CBD Oli)– Available in 25%,50% and 75% concentrations. Our proprietary engineering process has been developed to isolate and remove any unwanted compounds, while creating the maximum potency level of phytocannabinoids. State-of-the-art technology is employed to ensure a full-spectrum oil, that includes both high levels of Canabidiol, Cannabinoids and terpenes. This guarantees a consistent, pure, and premium product for our customers
The way I see it, the marriage of China’s position as the world’s supplier of hemp -- and its burgeoning semiconductor industry -- could be the key to China’s hegemony over the microchip industry. Semiconductors are traditionally made using silicon. Graphene semiconductors, however, could one day lead to computers that are a thousand times faster, consume significantly less power and are smaller than silicon semiconductors used in computer transistors. In application, graphene’s dwindling supply and costly manufacturing issues would still exist. Putting this all together, Mitlin’s research has sparked interest in the potential for hemp to create the next-generation semiconductor.
Do not use cannabis if you are pregnant or could become pregnant. There is some evidence that women who smoke cannabis during the time of conception or while pregnant may increase the risk of their child being born with birth defects. Pregnant women who continue to smoke cannabis are probably at greater risk of giving birth to low birthweight babies.
A Cochrane meta-analysis of 23 randomized RCTs reviewed studies conducted between 1975 and 1991 that investigated dronabinol or nabilone, either as monotherapy or as an adjunct to the conventional dopamine antagonists that were the standard antiemetics at that time. The chemotherapy regimens involved drugs with low, moderate, or high emetic potential. The meta-analysis graded the quality of evidence as low for most outcomes. The review concluded that individuals were more likely to report complete absence of N/V when they received cannabinoids compared with placebo, although they were more likely to withdraw from the study because of an adverse event. Individuals reported a higher preference for cannabinoids than placebo or prochlorperazine. There was no difference in the antiemetic effect of cannabinoids when compared with prochlorperazine. The authors concluded that Cannabis-based medications may be useful for treating refractory chemotherapy-induced N/V; however, they cautioned that their assessment may change with the availability of newer antiemetic regimens.
Short-term use of the drug impairs thinking and coordination. In long-term studies, teens who smoke marijuana have lower IQs later on, as well as structural differences in their brains, though scientists debate whether this is an effect of the drug or a result of habitual pot smokers seeking out less intellectually stimulating pursuits. A 2016 study on almost 300 students by the University of Montreal published in the journal Development and Psychopathology found that teens who start smoking around age 14 do worse on some cognitive tests by age 20 than non-smokers. They also have a higher school dropout rate. If they wait until age 17 to start, though, the smokers do not seem to have the same impairments, according to the study.
Soil characteristics, latitude and climatic stresses have been found to have significant effects on THC concentrations, and there are seasonal and even diurnal variations (Small 1979; Pate 1998b). However, the range of THC concentrations developed by low-THC cultivars (those typically with £0.3% THC) under different circumstances on the whole is limited, for the most part generally not varying more than 0.2 percentage points when grown in a range of circumstances, and usually less (note information in Scheifle et al. 1999; Scheifle 2000, Scheifle and Dragla 2000). Practically, this has meant in Canadian experience that a few cultivars have been eliminated from further commercial cultivation because they sometimes exceed the 0.3% level (‘Fedora 19’ and ‘Futura,’ authorized in 2000, have now been removed because some test results in several years exceeded 0.3%; ‘Finola’ and ‘Uniko B’ are under probation because of elevated levels), but on the whole most of the permitted cultivars have maintained highly consistent development of quite low levels of THC.
Our award-winning support staff, experienced cultivators, and network of healthcare practitioners are here to help remove barriers to medical cannabis. We’re honoured to be part of a movement that’s helping Canadians across the country access their medicine; and as we grow we will continue to provide patients with reliable access to safe, consistent, and effective medical cannabis.
Hemp’s greatest obstacle is its association with psychoactive cannabis, despite the important distinction that hemp contains only nominal amounts (no more than 0.3%) of the psychoactive ingredient, tetrahydrocannabinol (THC). Although the U.S. is the largest importer of hemp products according to the Hemp Business Journal (a New Frontier Data subsidiary), hemp itself has struggled to gain social acceptance in the country and elsewhere. For instance, current U.S. legislation only permits universities and states performing agricultural or academic research to cultivate hemp. However, the 2018 Farm Bill currently in Congress would grant hemp full legalization across the nation. Passage of this bill would be a key step in promoting public acceptance in the U.S. and elsewhere, allowing the country to participate in the rapidly growing global hemp market.
Food and beverage products containing CBD were introduced in the United States in 2017. Similar to energy drinks and protein bars which may contain vitamin or herbal additives, food and beverage items can be infused with CBD as an alternative means of ingesting the substance. In the United States, numerous products are marketed as containing CBD, but in reality contain little or none. Some companies marketing CBD-infused food products with claims that are similar to the effects of prescription drugs have received warning letters from the Food and Drug Administration for making unsubstantiated health claims.
In the meantime, some physicians are forging ahead — and cashing in. Joe Cohen is a doctor at Holos Health, a medical marijuana clinic in Boulder. I asked him what CBD is good for, and he read me a long list of conditions: pain, inflammation, nausea, vomiting, intestinal cramping, anxiety, psychosis, muscle spasms, hyperactive immune systems, nervous system degeneration, elevated blood sugar and more. He also claimed that CBD has anti-cancer properties and can regenerate brain cells and reduce the brain’s levels of amyloid beta — a kind of protein that’s been linked to Alzheimer’s disease. I asked for references, noting that most of these weren’t listed in the Academies report or a similar review published in the Journal of the American Medical Association. “I think you just have to Google search it,” he said. It’s true that a preliminary study found hints that cannabinoids might reduce beta amyloid proteins in human brain cells, but the study was done in cells grown in a lab, not in people. As for cancer, the FDA sent warning letters last year to four companies that were selling products that claimed to “prevent, diagnose, treat or cure” cancer.
For patients suffering from seizures, the legalization of cannabis would be a decisive turning point. Epilepsy makes you desperate. Seizures are painful, sometimes debilitating. And then there are the aftershocks: broken teeth, bruises and cuts, lost time, humiliation. People with epilepsy are often depressed, and have more than double the suicide rate of the population at large. Epilepsy is also associated with a syndrome known as Sudden Unexpected Death in Epilepsy, wherein a previously healthy person with epilepsy simply dies without warning or explanation. Grinding on without relief isn’t an option, but getting help is enormously expensive. Research conducted by Charles Begley, a professor of public health at the University of Texas, found that epilepsy treatment costs between $8,500 and $11,000 per year. Real Scientific Hemp Oil is no less expensive than its pharmaceutical counterparts, with no assistance from insurance. A single three-gram vial costs $149, while a six-pack of 10-gram tubes can cost $1,999 (or $1,599 on sale). HempMedsPx suggests a “serving size” of 0.5 ml twice daily. Only when these drugs are recognized as such will insurance pick up the tab.
Hi, I have had spondylolisthesis since age 11 which left me with extreme nerve pain...restless leg syndrome. Had 3 spinal ops and also had hip surgery 2 years ago. have asthma and hypothyroidism. I can deal with everything else but this nerve pain is insane. Used Gabapentin for 9 years and now its not in the market in Nairobi, Kenya where I live. Am on Lyrica, which is not working. I started Cbd oil in August but now found my body has become immune to the effects of pain releif I was getting. Can anyone suggest what strength oil/cbd supplement I should aim for? Currently am making flapjacks with weed, have one every night but this makes me high which I dont want. I still wake up in pain at night, please help.
Hemp is possibly one of the earliest plants to be cultivated. An archeological site in the Oki Islands near Japan contained cannabis achenes from about 8000 BC, probably signifying use of the plant. Hemp use archaeologically dates back to the Neolithic Age in China, with hemp fiber imprints found on Yangshao culture pottery dating from the 5th millennium BC. The Chinese later used hemp to make clothes, shoes, ropes, and an early form of paper. The classical Greek historian Herodotus (ca. 480 BC) reported that the inhabitants of Scythia would often inhale the vapors of hemp-seed smoke, both as ritual and for their own pleasurable recreation.
These CBD-only laws also attempt to impose some regulation on CBD oils, such as establishing how much CBD and THC such products must contain. For example, on June 1, the day I sat down with Hernandez in Fort Worth, Texas, Governor Greg Abbott signed the state’s Compassionate Use Act into law in Austin. The law requires that all CBD products contain no more than 0.5 percent THC and at least 10 percent CBD. However, the bill does not specify how the state plans to enforce this requirement. The law contains no language outlining how laboratories can test CBD products, what kinds of standards they would use, or who would regulate them.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.